novel.JPG

22 NOVEL DRUGS

Innovative products that serve unmet medical needs/significantly advance patient care. Have chemical structures that have never been approved before.

Adlyxin,  Anthim,  Axumin,  Briviact,  Cinqair, Defitelio, Epclusa, Eucrisa, Exondys 51, Lartruvo, Netspot, Nuplazid, Ocaliva, Rubraca, Spinraza, Taltz, Tecentriq, Venclexta, Xiidra, Zepatier, Zinbryta, Zinplava

SUMMARY

  • Impact: Public health, First-in-class,  Rare diseases
  • Innovation: Breakthrough, Fast Track, Pirority Review, Accelerated Approva
  • Predictability: Met PDUFA goal date
  • Access: First cycle approval, First approval in US

LEARN

Published by Drug & Device Advisory Group


Leave a Reply


Fill in your details below or click an icon to log in:

Gravatar

WordPress.com Logo



You are commenting using your WordPress.com account.
( Log Out / 
Change )

Google photo



You are commenting using your Google account.
( Log Out / 
Change )

Twitter picture



You are commenting using your Twitter account.
( Log Out / 
Change )

Facebook photo



You are commenting using your Facebook account.
( Log Out / 
Change )

Cancel

Connecting to %s